Gilead SciencesFRA:GIS +3.61%75 Days Payable is 42.65 as of Mar. 2026, which is 23% below its 10-year median of 55.31. GuruFocus rates FRA:GIS with a GF Score™ of 75/100 and a GF Value™ of €82.33 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 922 Drug Manufacturers companies, Gilead Sciences ranks worse than 82.75% on this metric.
The historical rank and industry rank for Gilead Sciences's Days Payable or its related term are showing as below:
FRA:GIS'
s Days Payable Range Over the Past 10 Years
Min: 40.38 Med: 55.31 Max: 102.11
Current: 41.46
During the past 13 years, Gilead Sciences's highest Days Payable was 102.11. The lowest was 40.38. And the median was 55.31.
FRA:GIS's Days Payable is ranked worse than 82.75% of 922
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs FRA:GIS: 41.46
Gilead Sciences's Days Payable
declined
from Mar. 2025 (47.31) to Mar. 2026 (42.65).
It may suggest that Gilead Sciencesaccelerated paying its suppliers.
Gilead Sciences Days Payable Related Terms
Gilead Sciences Days Payable Historical Data
* Premium members only.
The historical data trend for Gilead Sciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:GIS vs PFE, AMGN, BMY: Days Payable Comparison
For the Drug Manufacturers - General subindustry, Gilead Sciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gilead Sciences Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Gilead Sciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Gilead Sciences's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gilead Sciences (FRA:GIS) has a Days Payable of 42.65 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Gilead Sciences and its competitors. This is 23% below median its historical median of 55.31. Over the past decade, Gilead Sciences' Days Payable has ranged from 40.38 to 102.11. According to the industry distribution chart, Gilead Sciences ranks #763 out of 922 companies in the Drug Manufacturers industry, placing it in the top 82.8%.
Is Gilead Sciences' Days Payable too high?
Gilead Sciences' current Days Payable of 42.65 is 23% below median its 10-year median of 55.31. Over the past 10 years, this metric has ranged from a low of 40.38 to a high of 102.11. The Drug Manufacturers industry median Days Payable is 90.84. Gilead Sciences' value of 42.65 is 53% below this industry median. Based on the distribution chart, Gilead Sciences ranks #763 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Gilead Sciences has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gilead Sciences' Days Payable compare to PFE and AMGN?
According to the Drug Manufacturers industry distribution chart, Gilead Sciences ranks #763 out of 922 companies for Days Payable. This places Gilead Sciences in the lower half of its industry. The industry median Days Payable is 90.84. Gilead Sciences' value of 42.65 is 53% below this benchmark. Historically, Gilead Sciences' own Days Payable has ranged from 40.38 to 102.11 over the past decade. While the company's 10-year median is 55.31 vs. the industry median of 90.84, Gilead Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gilead Sciences's current Days Payable of 42.65 is 53% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Gilead Sciences and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gilead Sciences's current Days Payable is 42.65, which is 23% below median its own 10-year median of 55.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gilead Sciences stock overvalued right now?
Based on GuruFocus' analysis, Gilead Sciences (FRA:GIS) is currently considered Significantly Overvalued. The stock's GF Value™ is €82.33, compared to a current price of €114.38 — trading 38.9% above its estimated fair value. The current Days Payable is 42.65, which is 23% below median its 10-year median of 55.31 and 53% below the Drug Manufacturers industry median of 90.84. Gilead Sciences' overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Gilead Sciences (FRA:GIS), the current Days Payable is 42.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gilead Sciences (FRA:GIS) Overvalued in 2026?
Based on GuruFocus' analysis, Gilead Sciences stock appears to be overvalued.
The current stock price of €114.38 is trading 38.9% above its estimated GF Value™ of €82.33.
GuruFocus considers Gilead Sciences to be Significantly Overvalued.
Key valuation signals for FRA:GIS:
Days Payable: 42.65 (23% below median its 10-year median of 55.31)
GF Value™: €82.33 vs. price of €114.38 (38.9% above fair value)
Industry Position: 53% below the Drug Manufacturers median (#763 of 922)
No single metric tells the full story. See the FRA:GIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
75GF Score
Get the complete analysis for FRA:GIS
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GIS has been successfully added to your 
